Science

SBRT for oligoprogression in HCC, suggested by Nina Niu Sanford

Nina Niu Sanford/utswmed.org

Feb 2, 2025, 04:46

SBRT for oligoprogression in HCC, suggested by Nina Niu Sanford

Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared an article by Boyu Leng, et al. on X:

“We also consider SBRT for oligoprogression in HCC b/c:

high local control.
usually low toxicity.
allows pt to stay on 1st line chemo controlling non-progressive tumors.
saves 2nd line in case of future more widespread disease.

This is a nice paper lending support to that strategy.”

Maintaining first-line therapy plus radiotherapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma.

Authors: Boyu Leng, et al.

SBRT for oligoprogression in HCC, suggested by Nina Niu Sanford

Boyu Leng cancer fight against cancer Global fight against cancer HCC Massachusetts General Hospital oligoprogression OncoDaily Oncology radiation oncology SBRT

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC

Hesham ElGhazaly: Global Inclusion in Clinical Trials at Vision Europe 2025

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

Arnaud Lallouette: Servier and IDEAYA Partner to Bring a Promising Uveal Melanoma Treatment